2026 ICD-10-CM Diagnosis Code T80.89XSOther complications following infusion, transfusion and therapeutic injection, sequela
T80.89XS is a billable ICD-10-CM diagnosis code for other complications following infusion, transfusion and therapeutic injection, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Complication, sequela.
Code Identity
Code Classification
Present on Admission (POA)Billing
T80.89XS is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Abdominal hernia as complication of peritoneal dialysis
- Acute disorder of hemodialysis
- Acute megaloblastic anemia
- Acute megaloblastic anemia due to dialysis
- Acute megaloblastic anemia secondary to total parenteral nutrition
- Adverse reaction following injection of substance
- Adynamic bone disease
- Air in infusion or transfusion due to mechanical failure of apparatus
- Allergic transfusion reaction
- Alloimmune platelet transfusion refractoriness
- Alloimmune thrombocytopenia
- Allosensitization
- Blister at injection site
- Bloodstained peritoneal dialysis effluent
- Chronic kidney disease mineral and bone disorder
- Chronic polyserositis
- Complication of hemodialysis
- Dialysis dementia
- Dialysis disequilibrium syndrome
- Dialysis fluid adverse reaction
- Dialysis-associated ascites
- Dialysis-associated hypoxia
- Encapsulating peritoneal sclerosis associated with peritoneal dialysis
- Erythema at injection site
- Erythrocytosis due to autotransfusion
- Extravasation due to and following blood transfusion
- First use syndrome of dialysis
- Hematoma of dialysis access site
- Hemodialysis fluid adverse reaction
- Hemodialysis-associated pruritus
- Hemodialysis-associated pseudoporphyria
- Hemofiltration solution adverse reaction
- Hemolytic transfusion reaction
- Hemoperitoneum as complication of peritoneal dialysis
- Hemorrhage into peritoneal cavity
- Hemosiderosis
- Hydrothorax
- Hydrothorax as complication of peritoneal dialysis
- Hypercalcemia associated with chronic dialysis
- Hyperchloremic acidosis associated with dialysis
- Iatrogenic neonatal hyperglycemia
- Inadequate hemodialysis
- Inadequate peritoneal dialysis
- Infusion site swelling
- Injected limb mobility decreased
- Injection neuropathy
- Injection site anesthesia
- Injection site atrophy
- Injection site bruising
- Injection site burning
- Injection site cellulitis
- Injection site cyst
- Injection site dermatitis
- Injection site edema
- Injection site eruption
- Injection site fibrosis
- Injection site hemorrhage
- Injection site hypersensitivity
- Injection site indentation
- Injection site induration
- Injection site inflammation
- Injection site irritation
- Injection site itching
- Injection site malabsorption
- Injection site mass
- Injection site necrosis
- Injection site nerve damage
- Injection site pain
- Injection site paresthesia
- Injection site pigmentation change
- Injection site pruritus
- Injection site thrombosis
- Injection site urticaria
- Injury due to and following infusion
- Injury due to and following therapeutic injection
- Injury due to and following transfusion
- Intestinal obstruction due to a procedure
- Lipoatrophy caused by injected drug
- Lipogranuloma
- Localized lipoatrophy
- Long-term disorder of dialysis
- Loss of solute clearance
- Matrix stone formation during renal dialysis
- Mechanical failure of instrument or apparatus during infusion or transfusion
- Mechanical failure of instrument or apparatus during kidney dialysis
- Megaloblastic anemia due to hemodialysis
- Megaloblastic anemia due to hyperalimentation
- Meningitis due to and following intrathecal injection
- Meningitis following procedure
- Metabolic acidosis, NAG, acidifying salts
- Myelopathy post intrathecal injection of chemotherapeutic agent
- Neonatal hyperbilirubinemia following total parenteral nutrition
- Neonatal hyperglycemia
- Neonatal hyperglycemia due to iatrogenic intravenous therapy
- Neonatal polycythemia
- Non-allergic hypersensitivity reaction caused by dialysis membrane
- Non-allergic hypersensitivity reaction during dialysis
- Nontraumatic hemoperitoneum
- Osteonecrosis due to and following renal dialysis
- Pain during inflow of dialysate
- Pain during outflow of dialysate
- Penile sclerosing lipogranuloma
- Penile sclerosing lipogranuloma due to injection of substance
- Peritoneal dialysis solution adverse reaction
- Platelet alloimmunization
- Polycythemia neonatorum following blood transfusion
- Polyserositis
- Polyserositis syndrome of dialysis
- Porphyrin within reference range
- Post-dialysis dementia
- Pseudoporphyria
- Pulmonary transfusion reaction
- Reproductive system complication of procedure
- Sclerosing lipogranuloma
- Sclerosing peritonitis
- Sclerosing peritonitis as complication of peritoneal dialysis
- Sequelae of hyperalimentation
- Skin lesion associated with hemodialysis
- Swelling at injection site
- Thromboembolism following infusion, perfusion AND/OR transfusion
- Transfusion hemosiderosis
- Transfusion reaction caused by contaminant in blood
- Transfusion reaction caused by toxic effect of anticoagulant
- Transfusion reaction due to products of cell metabolism
- Ultrafiltration failure
- Underdialysis
- Urticarial transfusion reaction
Coding GuidelinesGuidance
The appropriate 7th character is to be added to each code from block Complications following infusion, transfusion and therapeutic injection (T80). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Hemosiderosis
conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the mononuclear phagocyte system, without demonstrable tissue damage. the name refers to the presence of stainable iron in the tissue in the form of hemosiderin.Hemosiderosis, Pulmonary
iron deposition within the lung. primary pulmonary hemosiderosis is characterized by hemoptysis; iron-deficiency anemia, and diffuse pulmonary hemorrhage as seen as transient pulmonary infiltrates on radiography. even though large amounts of iron are laid down in the lung, with normal or increased total body iron, anemia occurs because of inability of the erythron to use iron sequestered in pulmonary macrophages.Hydrothorax
a collection of watery fluid in the pleural cavity. (dorland, 27th ed)Mononuclear Phagocyte System
mononuclear cells with pronounced phagocytic ability that are distributed extensively in lymphoid and other organs. it includes macrophages and their precursors; phagocytes; kupffer cells; histiocytes; dendritic cells; langerhans cells; and microglia. the term mononuclear phagocyte system has replaced the former reticuloendothelial system, which also included less active phagocytic cells such as fibroblasts and endothelial cells. (from illustrated dictionary of immunology, 2d ed.)Ovarian Luteinized Thecoma Associated with Sclerosing Peritonitis
a rare usually bilateral luteinized thecoma that arises from the ovary and is associated with sclerosing peritonitis. it occurs mostly in premenopausal women. the ovarian tumor is benign but patients may develop intestinal obstruction due to the sclerosing peritonitis.Sclerosing Peritonitis
a rare peritoneal cavity disorder that is characterized by the development of dense fibrous tissue in the peritoneum and the creation of severe adhesions in the abdomen that result in partial or complete small bowel obstruction. it may be idiopathic or develop in patients who receive peritoneal dialysis treatment. patients present with abdominal distention and pain.Neonatal Hyperglycemia
blood glucose concentration above the upper limit of established reference ranges in a newborn.Erdheim-Chester Disease|ECD|Lipogranulomatosis|Polyostotic Sclerosing Histiocytosis
a very rare, multisystem non-langerhans cell histiocytosis that predominantly affects adults. it is characterized by the proliferation in the tissues of lipid-laden macrophages and the presence of multinucleated giant cells. it results in sclerosis of the long bones and failure of the affected organs. patients may present with bone pain, exophthalmos, ataxia, liver failure, kidney failure, and hypopituitarism.Farber Lipogranulomatosis
a very rare autosomal recessive metabolic disorder affecting lipid metabolism. it is caused by mutations in the asah1 gene and is characterized by fatty accumulation in the body tissues. patients develop lipogranulomas in the skin and internal organs, edema and pain in the joints and a hoarse voice. it may be associated with intellectual disability.Large Lipogranuloma Assessment|LPGNLMLG|Large Lipogranuloma|Large Lipogranuloma
an evaluation of the presence or degree of large lipogranuloma in a sample.Lipogranuloma
an inflammatory lesion comprised of lipoid material.Hydrothorax
the accumulation of serous fluid within the pleural cavity.Pseudoporphyria
a drug-induced photodermatosis characterized by skin fragility, erythema, and the appearance of tense bullae, erosions and scarring in the absence of abnormalities in porphyrin metabolism.
Convert T80.89XS to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T80.89XSOverview
Is T80.89XS a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report other complications following infusion, transfusion and therapeutic injection, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T80.89XS mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the other complications following infusion, transfusion and therapeutic injection itself has resolved, not the original event.
What MS-DRG does T80.89XS group to?
When other complications following infusion, transfusion and therapeutic injection, sequela is the principal diagnosis on an inpatient stay, it groups to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Is T80.89XS exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for other complications following infusion, transfusion and therapeutic injection, sequela on inpatient claims.
What is the ICD-9 equivalent of T80.89XS?
Under the General Equivalence Mappings, other complications following infusion, transfusion and therapeutic injection, sequela converts to ICD-9-CM 909.3 (late eff surg/med compl). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
